Final results from the PERUSE study of first-line pertuzumab plus trastuzumab plus a taxane for HER2-positive locally recurrent or metastatic breast cancer, with a multivariable ap... von Schneeweiss, A., Peretz-Yablonski, T., Nowecki, Z., Merot, J.-L., Pena-Murillo, C., Bachelot, T., Coudert, B., Nowecki, Z., Wardley, A., Puglisi, F., Montemurro, F., Hu, X., Gaafar, R., Li, H., Aktas, B., Tienghi, A., Miles, D., Lux, M., Menjon Beltran, S., Turner, N., Tong, Z., Boer, K., Horvath, Z., Susnjar, S., Matos, E., Garcia Estevez, L., Cruz, M., Bourgeois, H., von Schumann, R., Morales-Vásques, F., Voitko, N., Hicks, J., Barrett-Lee, P., Wheatley, D., Gozy, M., Latini, L., Barnadas Molins, A., Bratos, R., McCarthy, N., Kee, D., Artignan, X., Azribi, F., Jaafar, H., Augereau, P., Müller, V., Evron, E., Cascinu, S., El-Saghir, N., Ghosn, M., Oosterkamp, H.M., Kukulska, M., Levitt, N., Panwar, U., Rigg, A., Fein, L., Malik, L., Singer, C., Stoeger, H., Cedeño, M., Berdah, J.-F., Goncalves, A., Orfeuvre, H., Fried, G., Moscetti, L., Siddiqi, N., Arcediano Del Amo, A., McAdam, K., Dunn, G., Taylor, W., Hegg, R., Grosjean, J., Laplaige, P., Christensen, B., Zahm, D.-M., Inbar, M., Bonetti, A., van der Velden, A., van Warmerdam, L., Viñas Vilaro, G., Bachmeier, K., Beresford, M., Joffe, J., Nobre, A., Jiang, J., Padrik, P., Dohollou, N., Prulhiere, K., Ober, A., Alabiso, O., van de Wouw, A.J., Saadein, A., Abdelhafiez, N., Abulkhair, O., Llorente Domenech, R., Gil Raga, M., Rodriguez Sanchez, C., Torrego Garcia, J., Vicente Rubio, E., Jones, A., Alonso, I.

Volltext

Preliminary safety and efficacy of first-line pertuzumab combined with trastuzumab and taxane therapy for HER2-positive locally recurrent or metastatic breast cancer (PERUSE) von Schneeweiss, A., Puglisi, F., Peretz-Yablonski, T., Merot, J.-L., Miles, D., Coudert, Bruno, Errihani, Hassan, Dalenc, Florence, Barrett, Sophie, Beato, Carlos, Hu, Xichun, Perrin, Christophe, Ettl, Johannes, Li, Huiping, Cariello, Anna, Frassoldati, Antonio, Wronski, Andrzej, Menjón Beltrán, Salomón, Cicin, Irfan, Schmid, Peter, Juarez, Alejandro, Matos, Erika, Uslu, Ruchan, Wildiers, Hans, Bourgeois, Hugues, von Schumann, Raquel, Wojtukiewicz, Marek, Peron, Yann Izarzugaza, Wheatley, Duncan, De Boer, Richard, Jerusalem, Guy, Latini, Luciano, Barnadas Molins, Agusti, Martinez, Eduardo, Baird, Richard, McCarthy, Nicole, Greil, Richard, Juhasz-Boess, Ingolf, de la Cruz, Luis Ruiz, Del Val, Olga, Azribi, Fathi, Turner, Nicholas, Andrade, Jurandyr, Bernstein, Vanessa, Rayson, Daniel, Gennari, Alessandra, El-Saghir, Nagi, Kukulska, Monika, Pelaez, Ignacio, del Mar Gordon, Maria, Varughese, Mohini, Levitt, Nicola, Singer, Christian, Efremidou, Anna, Evron, Ella, Luigi, Cavanna, Garcia, Andres, Lopez Ceballos, Maria Helena, García, María, Arcediano, Alberto, McAdam, Karen, Humphreys, Alison, de Grève, Jacques, Joy, Anil, Sehdev, Sandeep, Kütner, Riina, Laplaige, Philippe, Christensen, Bernd, Fountzilas, Georgios, Fried, Georgeta, Giacobino, Alice, Bonetti, Andrea, Van der Velden, Annette, Vrijaldenhoven, Suzan, Andres Conejero, Raquel, Murias, Adolfo, Saura, Salvador, Poole, Christopher, Woodward, Natasha, Califaretti, Nadia, Jiang, Jun, Padrik, Peeter, Saarni, Outi, Genet, Dominique, Catala, Stéphanie, Facchini, Thomas, Repp, Roland, Schroeder, Willibald, Kahan, Zsuzsanna, Rosengarten, Ora, Alabiso, Oscar, Van de Wouw, Yes, Sousa, Gabriela, Jesús Florián Jerico, Marta Santisteban, Torrego, Juan Carlos, Rodriguez, Cesar, Llorca, Cristina, Galán, Antonio, Rodríguez, Robinson, Alonso, Isabel

Volltext

Preliminary safety and efficacy of first-line pertuzumab combined with trastuzumab and taxane therapy for HER2-positive locally recurrent or metastatic breast cancer (PERUSE) von Bachelot, T, Ciruelos, E, Schneeweiss, A, Puglisi, F, Peretz-Yablonski, T, Bondarenko, I, Paluch-Shimon, S, Wardley, A, Merot, J-L, du Toit, Y, Easton, V, Lindegger, N, Miles, D

Volltext

Preliminary safety and efficacy of first-line pertuzumab combined with trastuzumab and taxane therapy for HER2-positive locally recurrent or metastatic breast cancer (PERUSE) von Bachelot, T, Ciruelos, E, Schneeweiss, A, Puglisi, F, Peretz-Yablonski, T, Bondarenko, I, Paluch-Shimon, S, Wardley, A, Merot, J.-L, du Toit, Y, Easton, V, Lindegger, N, Miles, D, PERUSE investigators

Volltext

Final results from the PERUSE study of first-line pertuzumab plus trastuzumab plus a taxane for HER2-positive locally recurrent or metastatic breast cancer, with a multivariable ap... von Miles, D, Ciruelos, E, Schneeweiss, A, Puglisi, F, Peretz-Yablonski, T, Campone, M, Bondarenko, I, Nowecki, Z, Errihani, H, Paluch-Shimon, S, Wardley, A, Merot, J-L, Trask, P, du Toit, Y, Pena-Murillo, C, Revelant, V, Klingbiel, D, Bachelot, T, PERUSE investigators

Volltext bestellen